November 22nd 2024
A phase 1 trial of α-lactalbumin vaccine for the treatment of patients with triple-negative breast cancer demonstrated safety and tolerability.
November 21st 2024
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Controversies and Conversations About HER2-Expressing Breast Cancer… Advances in Management from HER2-Low to Positive Disease
View More
Emerging Treatments and Evolving Paradigms in HER2-Low Breast Cancer
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Matching the Right Patients to the Right Therapies in TNBC: Case-Based Applications of Immune Checkpoint Inhibitors, PARP Inhibitors, and TROP2-Targeted ADCs
View More
Clinical Vignettes™: The Experts Explain How They Integrate PET Imaging into Metastatic HR+ Breast Cancer Care Settings
View More
School of Breast Oncology® Live Video Webcast: Clinical Updates from San Antonio
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Next-Generation Endocrine Therapy for ER+/HER2- Breast Cancer: Addressing Unmet Needs and Keys to Optimization in Clinical Practice
View More
Identifying Health Care Inequities in Screening, Diagnosis, and Trial Access for Breast Cancer Care: Taking Action With Evidence-Based Solutions
View More
Empowering Breast Cancer Patients with Non-Opioid Pain Management Innovations
View More
Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Community Practice Connection™: Leveraging Multidisciplinary Teams in an Evolving Treatment Landscape for Early- Stage HR+, HER2- Breast Cancer
View More
How We Do It™: Defining HER2 Low on Your Pathology Reports to Make Informed Decisions in Breast Cancer Treatment
View More
Clinical Case Vignette Series™: 41st Annual Miami Breast Cancer Conference®
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
24th Annual International Congress on the Future of Breast Cancer® West
July 18-19, 2025
Register Now!
24th Annual International Congress on the Future of Breast Cancer® East
July 11-12, 2025
Register Now!
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Community Practice Connections™: 23rd Annual International Congress on the Future of Breast Cancer West
View More
School of Breast Oncology® (SOBO) Slide & Lecture Library
Joyce O’Shaughnessy, MD
View More
Ribociclib Granted Breakthrough Therapy Designation by FDA for HR+/HER2- Premenopausal Breast Cancer
January 3rd 2018Based on results of the phase III MONALEESA-7 trial, ribociclib (Kisqali) has been granted a breakthrough therapy designation by the FDA for use in combination with tamoxifen or an aromatase inhibitor as frontline treatment for pre- or perimenopausal women with hormone receptor–positive, HER2-negative advanced or metastatic breast cancer.
Read More
Stereotactic Radiotherapy Device Given Green Light for Early Breast Cancer by FDA
December 26th 2017Based on findings from a 17-patient study, a novel breast-specific stereotactic body radiotherapy (SBRT) device known as GammaPod has been approved by the FDA as a treatment for patients with early breast cancer.<br /> <br />
Read More
Adjuvant Pertuzumab Regimen Receives FDA Approval for HER2+ Breast Cancer
December 21st 2017Based on findings from the APHINITY trial, pertuzumab (Perjeta) has been approved by the FDA in combination with trastuzumab (Herceptin) and chemotherapy for the adjuvant treatment of patients with HER2-positive early breast cancer at high risk for recurrence.
Read More
Ongoing Trials in Other Settings for CDK4&6 Inhibitors in Breast Cancer
December 19th 2017Prospects for patients with breast cancer have improved with the use of CDK4&6 inhibitors, including palbociclib, ribociclib, and abemaciclib; however, the effects of these inhibitors in many subsets of patients have not been investigated.
Read More
Approved CDK4&6 Inhibitors in Breast Cancer
December 19th 2017The development of CDK4&6 inhibitors has provided promising data regarding this new therapeutic option for patients with cancer, particularly for patients with breast cancer. Currently, there are 3 FDA-approved CDK4&6 inhibitors for the treatment of patients with breast cancer.
Read More
Rationale For CDK4&6 Inhibition in Breast Cancer
December 19th 2017The second most common cancer worldwide, breast cancer remains a significant global burden despite decreased incidence in Western countries. Breast cancer is the fifth leading cause of cancer death in the United States, with more than 40,000 estimated deaths in 2017.
Read More
Olaparib/Durvalumab Combo Demonstrates 80% DCR in HR+/HER2- Breast Cancer
December 16th 2017According to phase II findings from the MEDIOLA trial presented at the 2017 San Antonio Breast Cancer Symposium, the combination of olaparib and durvalumab demonstrated a disease control rate of 80% for pretreated patients with germline <em>BRCA-</em>mutated, HER2-negative metastatic breast cancer, according to phase II findings from the MEDIOLA trial.
Read More
Abemaciclib/Pembrolizumab Combo Shows Signs of Activity in HR+/HER2- Breast Cancer
December 16th 2017According to early results from a pilot trial presented in a poster at the 2017 San Antonio Breast Cancer Symposium, the combination of abemaciclib and pembrolizumab showed preliminary signs of activity without additive toxicity for patients with pretreated HR-positive, HER2-negative metastatic breast cancer.
Read More
Progress for TNBC Seen Across Treatment Modalities
December 15th 2017Promising clinical trial results have been seen with the exploration of new and existing treatment approaches for patients with triple-negative breast cancer (TNBC) on several fronts, including chemotherapy, immunotherapy, novel antibodies, and agents targeting the PI3K/mTOR/AKT pathway, according to David W. Miles, MB BS, BSc, MD. During a presentation at the <em>1st Annual </em>Paris Breast Cancer Conference hosted by the Physicians Education Resource®, LLC, Miles, a consultant medical oncologist at West Hertfordshire Hospitals in England, provided his perspective on potential new treatment options for patients with TNBC.
Read More
Blackwell Inaugurated as VP of Early Phase Development and Immuno-Oncology at Lilly
December 14th 2017Eli Lilly and Company has announced that Kimberly L. Blackwell, MD, a pioneer in breast cancer research, will serve as its vice president of early phase development and immuno-oncology. She will begin her new role on March 12, 2018.<br />
Read More
Phase I Trial Demonstrates Activity of Antibody-Drug Conjugate Targeting LIV-1 in TNBC
December 13th 2017Treatment with ladiratuzumab vedotin demonstrated an estimated median progression-free survival (PFS) of 11.6 weeks for patients with heavily pretreated metastatic triple-negative breast cancer (TNBC) treated with the recommended phase II dose of the antibody–drug conjugate, according to results of a phase I study presented during the 2017 San Antonio Breast Cancer Symposium.
Read More
5-Year Follow-Up of CALGB 40502 Study in TNBC
December 13th 2017Hope S. Rugo, MD, professor of medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses the 5-year follow-up of the CALGB 40502 study for patients with triple-negative breast cancer (TNBC).
Watch
OlympiAD Trial Demonstrates Acceptable Toxicity Profile for Olaparib in BRCA+, HER2- Breast Cancer
December 13th 2017Treatment discontinuation due to toxicity was less frequent with olaparib (Lynparza) monotherapy compared with chemotherapy in patients with HER2-negative metastatic breast cancer and a germline <em>BRCA</em> mutation in the phase III OlympiAD study.
Read More
GeparSepto Trial Demonstrates Improved Survival in High-Risk Early Breast Cancer With Nab-Paclitaxel
December 11th 2017In findings from the phase III GeparSepto trial presented during the 2017 San Antonio Breast Cancer Symposium, long-term disease-free survival rates were improved with neoadjuvant nab-paclitaxel (Abraxane) compared with standard paclitaxel in patients with high-risk early breast cancer.
Read More
Survival Improved With Nab-Paclitaxel in TNBC Subset
December 9th 2017Survival rates improved with nab-paclitaxel (Abraxane) therapy compared with paclitaxel in patients with triple-negative breast cancer (TNBC) more than in other patient subsets, according to findings from a post-hoc analysis from the CALGB 40502/NCCTG N063H clinical trial.
Read More
CTC Detection Associated With High Breast Cancer Recurrence Risk
December 9th 2017Results of a prospective clinical trial demonstrated that the detection of positive circulating tumor cells in the blood 5 years after hormone receptor-positive, HER2-negative breast cancer diagnosis was associated with an increased risk for late recurrence.
Read More
Ovarian Function, Fertility Potentially Protected By Hormone Analog For Women Treated With Chemo
December 8th 2017Treatment with a gonadotropin-releasing hormone analog could potentially preserve fertility and protect ovarian function in premenopausal woman being treated with chemotherapy for early-stage breast cancer, according to the results of a meta-analysis presented at the 2017 San Antonio Breast Cancer Symposium.
Read More
SOLD Trial Maintains Benefit of 1 Year of Adjuvant Trastuzumab for Early Stage HER2+ Breast Cancer
December 8th 2017Results of the phase III SOLD trial maintained the benefit of 12 months of adjuvant treatment with trastuzumab (Herceptin) for patients with early stage HER2-positive breast cancer, as the trial failed to demonstrate noninferiority for 9 weeks of trastuzumab versus the standard 1-year period, when added to chemotherapy.
Read More
DFS Maintained in HR+ Breast Cancer With Fewer Years of AI Therapy
December 8th 2017Disease-free survival is maintained in women with postmenopausal hormone receptor-positive breast cancer treated with aromatase inhibitors, even when the treatment is only given for 2 years in comparison with the standard 5 years of additional aromatase inhibitor therapy, according to findings from the phase III ABCSG-16 trial presented at the 2017 San Antonio Breast Cancer Symposium.
Read More
Enzalutamide Shows Promise in HR+ Breast Cancer
December 7th 2017Denise Yardley, MD, senior investigator, Sarah Cannon Research Institute, discusses the results from a recent phase II trial evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive breast cancer.
Watch
Getting Genetic Testing to Those Who Need It
December 7th 2017Julie Nangia, MD, assistant professor of Medicine, Baylor College of Medicine, discusses getting genetic testing for patients. While the NCCN has guidelines of who should be tested, it may also be possible for physicians to write a letter of medical necessity for other people, such as Ashkenazi Jewish women, who have higher rates of BRCA mutations.
Watch
Dosing Modifications Shown to Improve Outcomes In Breast Cancer
December 7th 2017Early-stage breast cancer recurrence and mortality was reduced by shortening the intervals between chemotherapy cycles or administering the drugs sequentially compared with standard dosing techniques, according to meta-analysis results presented at the 2017 San Antonio Breast Cancer Symposium.
Read More
The Takeaway Message from the NSABP-47 Trial in HER2-low Breast Cancer
December 7th 2017Mothaffar F. Rimawi, MD, associate professor and director of clinical research at the Lester and Sue Smith Breast Center at Baylor College of Medicine, discusses the NSABP B-47 study, which explored the value of trastuzumab (Herceptin) plus standard adjuvant chemotherapy in breast cancer patients with low levels of HER2 protein.
Watch
Disease Control Rate of 45% Achieved With Sacituzumab Govitecan in Heavily Pretreated TNBC
December 7th 2017An overall disease control rate of 45% was achieved with sacituzumab govitecan (IMMU-132) therapy in patients with heavily pretreated metastatic triple-negative breast cancer (mTNBC), according to updated findings of a study presented at the 2017 San Antonio Breast Cancer Symposium (SABCS).
Read More